AI Finds Increased Hunger in Unapproved Retatrutide Users — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Pennsylvania researchers analyzed nearly 150,000 Reddit posts using AI and identified increased appetite as the most commonly reported symptom among users claiming to take unapproved retatrutide, contrary to its intended appetite-suppressing effect.
- Retatrutide activates three hormone receptors involved in appetite and metabolism and is currently in Phase 3 clinical trials, with no regulatory approval yet for human use.
- Reddit users discussing unapproved retatrutide reported more sleep disturbances, elevated heart rates, and muscle-related symptoms compared to users of approved GLP-1 drugs like semaglutide and tirzepatide, while reporting fewer gastrointestinal issues.
- AI systems translated informal symptom descriptions from Reddit into standardized medical terms, enabling large-scale analysis of self-reported experiences that would be impractical to conduct manually.
- Neil Sehgal, the study’s first author, emphasized that the findings do not prove causation, as users may not be taking genuine retatrutide and could be influenced by other substances or underlying health conditions.
- Jena Shaw Tronieri noted that people obtaining unapproved versions of the drug likely differ from clinical trial participants in behavior, health profiles, and concurrent drug use, complicating interpretation of symptom reports.
Why it matters: The study identifies a paradoxical increase in appetite among users of an experimental appetite-suppressing drug, suggesting either novel biological effects or contamination in gray-market formulations. This divergence from clinical trial data creates urgency for regulators and drug developers to monitor informal markets, where unverified products may expose users to unknown risks while bypassing established safety systems.
Ask SkimNews
